APEA PMHNP Pre-Predictor Exam
AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines |
APEA PMHNP Pre-Predictor Exam AND ANSWERS ALREADY |
Comprehensive Examination
APEA PMHNP Pre-Predictor Exam AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated
Per Latest Guidelines | Graded A+ actual exam preparation
INTRODUCTION
This document is an important and very helpful preparation
resource for APEA PMHNP Pre-Predictor Exam AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines | Graded A+. Every item uses a
focused exam stem, four response options, a keyed response,
and a clear rationale, making it easier to understand the
subject, spot distractors, and build real exam confidence.
Page 1
, Question 1
A PMHNP in a full-practice-authority state wishes to initiate buprenorphine for
opioid use disorder but has not completed the DEA MATE Act training. Under
current federal requirements, which action is legally permissible?
A. Prescribe only after obtaining a separate DATA-2000 waiver from
SAMHSA.
B. Prescribe buprenorphine only for pain, not for opioid use disorder.
C. Prescribe buprenorphine for opioid use disorder after completing the
required 8-hour DEA training attestation.
D. Prescribe only with a collaborating physician's co-signature.
Correct Answer: C - Prescribe buprenorphine for opioid use
disorder after completing the required 8-hour DEA training
attestation.
RATIONALE
The Consolidated Appropriations Act of 2023 eliminated the X-waiver
(DATA-2000) and instead requires DEA-registered prescribers to attest
to completing at least 8 hours of training on treating and managing
patients with opioid or other substance use disorders via the MATE
Act. Option A is outdated because the X-waiver no longer exists; B
and D misstate current federal law, as no separate pain-only restriction
or physician co-signature is federally mandated.
Question 2
A patient with schizophrenia spectrum illness has failed adequate trials of two
different second-generation antipsychotics. Which finding would most strongly
prompt initiation of clozapine rather than a third non-clozapine antipsychotic?
A. Persistent auditory hallucinations despite 6 weeks of risperidone at 6
mg/day
B. Recurrent suicidal ideation with two prior attempts in the context of
command hallucinations
C. Metabolic syndrome with BMI 34 and HbA1c 6.1%
Page 2
, D. Extrapyramidal symptoms on aripiprazole requiring benztropine
Correct Answer: B - Recurrent suicidal ideation with two prior
attempts in the context of command hallucinations
RATIONALE
Clozapine is uniquely indicated for suicidality in schizophrenia
(InterSePT trial) and is the only antipsychotic with FDA approval for
reducing recurrent suicidal behavior. Metabolic syndrome is a relative
concern but not a contraindication; EPS on aripiprazole argues for
switching but not specifically clozapine. Persistent hallucinations
alone warrant clozapine only after two failed trials, but suicidality is
the most compelling and evidence-based trigger.
Question 3
A patient with advanced dementia has severe agitation, and the family requests
a definitive medication plan. Which agent has the strongest evidence for
reducing agitation in Alzheimer's disease but requires monitoring for
bradycardia and QT prolongation?
A. Quetiapine
B. Citalopram
C. Risperidone
D. Donepezil
Correct Answer: B - Citalopram
RATIONALE
Citalopram has the strongest evidence for reducing agitation in
Alzheimer's disease, though it requires ECG monitoring for QT
prolongation and bradycardia. Quetiapine and risperidone are used
off-label with modest efficacy and higher mortality risk. Donepezil
may worsen agitation and does not primarily treat it.
Page 3
, Question 4
A patient on chronic high-dose haloperidol develops a drug-induced movement
disorder that is suppressed by benztropine but reappears when benztropine is
reduced. Which pathophysiologic mechanism best explains this phenomenon?
A. Supersensitivity of nigrostriatal D2 receptors after chronic blockade
B. Loss of presynaptic dopamine terminals in the substantia nigra
C. Excess cholinergic activity in the striatum from anticholinergic
withdrawal
D. Direct toxicity to GABAergic medium spiny neurons
Correct Answer: A - Supersensitivity of nigrostriatal D2
receptors after chronic blockade
RATIONALE
This describes tardive dyskinesia, caused by nigrostriatal D2 receptor
supersensitivity after chronic antipsychotic blockade; anticholinergics
can transiently mask it. Options B and D describe Parkinson's disease
or neurotoxicity, not TD, and C mischaracterizes the cholinergic role.
Question 5
A prepubertal child presents with severe, recurrent, explosive temper outbursts
that are grossly out of proportion to provocation, occurring at least three times
weekly for over a year, with persistent irritable mood between outbursts and
onset before age 10. Which DSM-5-TR diagnosis is most appropriate, and
which differential must be explicitly excluded?
A. Disruptive mood dysregulation disorder; exclude bipolar I disorder
B. Intermittent explosive disorder; exclude oppositional defiant disorder
C. Oppositional defiant disorder; exclude major depressive disorder
D. Pediatric bipolar I disorder; exclude disruptive mood dysregulation
disorder
Correct Answer: A - Disruptive mood dysregulation disorder;
exclude bipolar I disorder
Page 4
AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines |
APEA PMHNP Pre-Predictor Exam AND ANSWERS ALREADY |
Comprehensive Examination
APEA PMHNP Pre-Predictor Exam AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated
Per Latest Guidelines | Graded A+ actual exam preparation
INTRODUCTION
This document is an important and very helpful preparation
resource for APEA PMHNP Pre-Predictor Exam AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions
| Updated Per Latest Guidelines | Graded A+. Every item uses a
focused exam stem, four response options, a keyed response,
and a clear rationale, making it easier to understand the
subject, spot distractors, and build real exam confidence.
Page 1
, Question 1
A PMHNP in a full-practice-authority state wishes to initiate buprenorphine for
opioid use disorder but has not completed the DEA MATE Act training. Under
current federal requirements, which action is legally permissible?
A. Prescribe only after obtaining a separate DATA-2000 waiver from
SAMHSA.
B. Prescribe buprenorphine only for pain, not for opioid use disorder.
C. Prescribe buprenorphine for opioid use disorder after completing the
required 8-hour DEA training attestation.
D. Prescribe only with a collaborating physician's co-signature.
Correct Answer: C - Prescribe buprenorphine for opioid use
disorder after completing the required 8-hour DEA training
attestation.
RATIONALE
The Consolidated Appropriations Act of 2023 eliminated the X-waiver
(DATA-2000) and instead requires DEA-registered prescribers to attest
to completing at least 8 hours of training on treating and managing
patients with opioid or other substance use disorders via the MATE
Act. Option A is outdated because the X-waiver no longer exists; B
and D misstate current federal law, as no separate pain-only restriction
or physician co-signature is federally mandated.
Question 2
A patient with schizophrenia spectrum illness has failed adequate trials of two
different second-generation antipsychotics. Which finding would most strongly
prompt initiation of clozapine rather than a third non-clozapine antipsychotic?
A. Persistent auditory hallucinations despite 6 weeks of risperidone at 6
mg/day
B. Recurrent suicidal ideation with two prior attempts in the context of
command hallucinations
C. Metabolic syndrome with BMI 34 and HbA1c 6.1%
Page 2
, D. Extrapyramidal symptoms on aripiprazole requiring benztropine
Correct Answer: B - Recurrent suicidal ideation with two prior
attempts in the context of command hallucinations
RATIONALE
Clozapine is uniquely indicated for suicidality in schizophrenia
(InterSePT trial) and is the only antipsychotic with FDA approval for
reducing recurrent suicidal behavior. Metabolic syndrome is a relative
concern but not a contraindication; EPS on aripiprazole argues for
switching but not specifically clozapine. Persistent hallucinations
alone warrant clozapine only after two failed trials, but suicidality is
the most compelling and evidence-based trigger.
Question 3
A patient with advanced dementia has severe agitation, and the family requests
a definitive medication plan. Which agent has the strongest evidence for
reducing agitation in Alzheimer's disease but requires monitoring for
bradycardia and QT prolongation?
A. Quetiapine
B. Citalopram
C. Risperidone
D. Donepezil
Correct Answer: B - Citalopram
RATIONALE
Citalopram has the strongest evidence for reducing agitation in
Alzheimer's disease, though it requires ECG monitoring for QT
prolongation and bradycardia. Quetiapine and risperidone are used
off-label with modest efficacy and higher mortality risk. Donepezil
may worsen agitation and does not primarily treat it.
Page 3
, Question 4
A patient on chronic high-dose haloperidol develops a drug-induced movement
disorder that is suppressed by benztropine but reappears when benztropine is
reduced. Which pathophysiologic mechanism best explains this phenomenon?
A. Supersensitivity of nigrostriatal D2 receptors after chronic blockade
B. Loss of presynaptic dopamine terminals in the substantia nigra
C. Excess cholinergic activity in the striatum from anticholinergic
withdrawal
D. Direct toxicity to GABAergic medium spiny neurons
Correct Answer: A - Supersensitivity of nigrostriatal D2
receptors after chronic blockade
RATIONALE
This describes tardive dyskinesia, caused by nigrostriatal D2 receptor
supersensitivity after chronic antipsychotic blockade; anticholinergics
can transiently mask it. Options B and D describe Parkinson's disease
or neurotoxicity, not TD, and C mischaracterizes the cholinergic role.
Question 5
A prepubertal child presents with severe, recurrent, explosive temper outbursts
that are grossly out of proportion to provocation, occurring at least three times
weekly for over a year, with persistent irritable mood between outbursts and
onset before age 10. Which DSM-5-TR diagnosis is most appropriate, and
which differential must be explicitly excluded?
A. Disruptive mood dysregulation disorder; exclude bipolar I disorder
B. Intermittent explosive disorder; exclude oppositional defiant disorder
C. Oppositional defiant disorder; exclude major depressive disorder
D. Pediatric bipolar I disorder; exclude disruptive mood dysregulation
disorder
Correct Answer: A - Disruptive mood dysregulation disorder;
exclude bipolar I disorder
Page 4
